Last reviewed · How we verify
NCT05995444
A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects
Phase 1 trial testing Epetraborole and matching placebo in Healthy Volunteers in 24 participants. Completed in 3 August 2023.
26 July 2023
Quick facts
| Lead sponsor | AN2 Therapeutics, Inc |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | basic science |
| Enrollment | 24 |
| Start date | 5 June 2023 |
| Primary completion | 26 July 2023 |
| Estimated completion | 3 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Epetraborole and matching placebo — full drug profile →
- Epetraborole — full drug profile →
- Placebo
- Moxifloxacin (moxifloxacin) — full drug profile →
Conditions studied
- Healthy Volunteers — all drugs for Healthy Volunteers →
Sponsor
AN2 Therapeutics, Inc — full company profile →
Who can join
Adults 18 to 65, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A single-center, 4-way crossover study to evaluate the effect of single therapeutic and supratherapeutic oral doses of epetraborole on the heart rate (HR) corrected QT interval (QTc) by assessing concentration-QT (C-QT) relationship using exposure-response modeling.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05995444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Epetraborole
Trials testing the same drug.
- NCT05327803 — Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease · Phase 2, PHASE3 · terminated
- NCT05283746 — A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function · Phase 1 · completed
- NCT04892641 — Phase 1 Study of Epetraborole Tablets · Phase 1 · completed
Other recruiting trials for Healthy Volunteers
Currently open trials in the same condition.
- NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
- NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
- NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting
Other AN2 Therapeutics, Inc trials
Trials by the same sponsor.
- NCT06089668 — An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis · completed
- NCT05327803 — Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease · Phase 2, PHASE3 · terminated
- NCT05283746 — A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function · Phase 1 · completed
- NCT04892641 — Phase 1 Study of Epetraborole Tablets · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05995444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AN2 Therapeutics, Inc
- Last refreshed: 21 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05995444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing